As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

Apellis Pharmaceuticals Inc (APLS:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. The Company’s product candidates include AT-007, AT-001, and AT-003. Its AT-007 is a central nervous system (CNS) penetrant ARI for the treatment of CNS rare diseases, including Galactosemia, sorbitol dehydrogenase (SORD) deficiency, and PMM2-CDG. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is being developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Applied Therapeutics Inc

Archrock Partners, L.P. is engaged in natural gas compression industry in the United States. The Company's contract operations services include designing, sourcing, owning, installing, operating, servicing, repairing and maintaining equipment to provide natural gas compression services to its customers. It provides contract operations services, including the personnel, equipment, tools, materials and supplies to meet its customers' natural gas compression needs. Archrock General Partner, L.P., its general partner, is a subsidiary of Archrock and has responsibility for conducting its business and for managing its operations. The Company utilizes both slow and high speed reciprocating compressors primarily driven by internal natural gas fired combustion engines. Its customers include companies engaged in various aspects of the oil and natural gas industry, including natural gas producers, processors, gatherers, transporters and storage providers.

Archrock Partners LP

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.

APLS

Buy

👑 Overview

📈

N/A

Annual Growth

🌏

0

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$86.97

How our community is investing

0

N/A

N/A

N/A

N/A

APLS investor breakdown

💵 Income of investors

👶 Age of investors

🙋 Legal gender of investors

$1.30 USD

Find Out More

$15.30 USD

Find Out More

Buy